2024
DOI: 10.1001/jamanetworkopen.2024.48215
|View full text |Cite
|
Sign up to set email alerts
|

Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia

Sean P. Collins,
Matthew S. Shotwell,
Jeffrey R. Strich
et al.

Abstract: ImportanceFostamatinib, a spleen tyrosine kinase inhibitor, has been reported to improve outcomes of COVID-19.ObjectiveTo evaluate the efficacy and safety of fostamatinib in adults hospitalized with COVID-19 and hypoxemia.Design, Setting, and ParticipantsThis multicenter, phase 3, placebo-controlled, double-blinded randomized clinical trial was conducted at 41 US sites and 21 international sites between November 17, 2021, and September 27, 2023; the last follow-up visit was December 31, 2023. Participants were… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 29 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?